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Abstract
Aims/hypothesis Elevated levels of lipoprotein(a) [Lp(a)] are
an independent risk factor for cardiovascular disease (CVD),
particularly in individuals with type 2 diabetes. Although
weight loss improves conventional risk factors for CVD in
type 2 diabetes, the effects on Lp(a) are unknown and may
influence the long-term outcome of CVD after diet-induced
weight loss. The aim of this clinical study was to determine the
effect of diet-induced weight loss on Lp(a) levels in obese
individuals with type 2 diabetes.
Methods Plasma Lp(a) levels were determined by
immunoturbidimetry in plasma obtained before and after
3–4 months of an energy-restricted diet in four independent
study cohorts. The primary cohort consisted of 131
predominantly obese patients with type 2 diabetes (cohort 1),
all participants of the Prevention OfWeight Regain in diabetes
type 2 (POWER) trial. The secondary cohorts consisted of 30
obese patients with type 2 diabetes (cohort 2), 37 obese
individuals without type 2 diabetes (cohort 3) and 26 obese
individuals without type 2 diabetes who underwent bariatric
surgery (cohort 4).
Results In the primary cohort, the energy-restricted diet
resulted in a weight loss of 9.9% (95% CI 8.9, 10.8) and
improved conventional CVD risk factors such as
LDL-cholesterol levels. Lp(a) levels increased by 14.8 nmol/l
(95%CI 10.2, 20.6). In univariate analysis, the change in Lp(a)
correlated with baseline Lp(a) levels (r = 0.38, p < 0.001) and
change in LDL-cholesterol (r = 0.19, p = 0.033). In cohorts 2
and 3, the weight loss of 8.5% (95% CI 6.5, 10.6) and 6.5%
(95% CI 5.7, 7.2) was accompanied by a median increase
in Lp(a) of 13.5 nmol/l (95% CI 2.3, 30.0) and 11.9 nmol/l
(95% CI 5.7, 19.0), respectively (all p < 0.05). When cohorts
1–3 were combined, the diet-induced increase in Lp(a)
correlated with weight loss (r = 0.178, p = 0.012). In cohort
4, no significant change in Lp(a) was found (−7.0 nmol/l; 95%
CI -18.8, 5.3) despite considerable weight loss (14.0%; 95%
CI 12.2, 15.7).
Conclusions/interpretation Diet-induced weight loss was
accompanied by an increase in Lp(a) levels in obese
individuals with and without type 2 diabetes while
conventional CVD risk factors for CVD improved. This
increase in Lp(a) levels may potentially antagonise the
beneficial cardiometabolic effects of diet-induced weight
reduction.
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Introduction
Cardiovascular disease (CVD) is the main cause of morbidity
and mortality in obese individuals with and without type 2
diabetes [1–3]. The risk of CVD in obese patients with
type 2 diabetes has been attributed to age, smoking,
hyperglycaemia, hypertension and dyslipidaemia [2]. Weight
loss via lifestyle programmes, consisting of diet and physical
activity, results in an improvement in conventional CVD risk
factors and is first-line therapy to slow down the development
of type 2 diabetes and the progression of its complications in
overweight or obese individuals [4, 5].
Lipoprotein a [Lp(a)] is an independent risk factor for CVD
[6–12]. Lp(a) consists of an LDL-like particle with an addition-
al apolipoprotein (a) [Apo(a)] attached to it. Plasma Lp(a)
concentrations vary highly between individuals and are largely
genetically determined by the number of copies of kringle-IV
type 2 (KIV-2) in the Apo(a) protein [Apo(a) isoform] [13–16].
A low number of copies of KIV-2, associated with elevated
levels of Lp(a), has been shown to increase the risk of CVD
[17]. A recent prospective population-based cohort of 56,367
participants showed a significantly higher contribution of Lp(a)
levels to CVD and risk of myocardial infarction in patients with
type 2 diabetes than in control participants without type 2 dia-
betes [18]. About 25% of the variance in Lp(a) levels has been
attributed to lifestyle [19]. Weight loss in obese individuals has
been reported to affect Lp(a) levels, but the results are contro-
versial [20–23]. The effect of weight loss on plasma Lp(a)
levels in type 2 diabetes has not yet been determined.
The aim of the current study was to determine the effect of
diet-induced weight loss on Lp(a) levels in obese patients with
type 2 diabetes. In order to confirm our findings we also
examined the effect of weight loss on Lp(a) levels in three
independent cohorts of obese patients with or without type 2
diabetes. As a secondary aim, we assessed the influence of
Apo(a) isoforms on diet-induced changes in Lp(a) level in
individuals with type 2 diabetes.
Methods
Participants and interventions The effect of weight loss was
examined in four independent cohorts. The primary cohort
(cohort 1, n = 131) consisted of overweight and obese
individuals (BMI >27 kg/m2, 93% obese) with type 2 diabetes
who participated in the run-in phase of the Prevention Of
Weight Regain (POWER) trial (trial registration no.
NTR2264) [24]. This trial aimed to study long-term weight
maintenance after the run-in diet phase. The sample size of
131 patients was sufficient to find a difference of 10.6 nmol/l
(5 mg/dl) in Lp(a) level with a baseline-to-end correlation of
0.95 between the measurements, an α of 0.05 and a power of
0.90. The diet started with 8 weeks of a diet very low in energy
(very low calorie diet [VLCD]) of approximately 3000 kJ
(750 kcal) per day, consisting of two meal replacements
(Glucerna, Abbott Nutrition, Lake Forest, IL, USA) and a
small dinner daily. Thereafter, energy intake was slowly
increased up to approximately 5500 kJ (1300 kcal) per day
(a low-energy diet) over 12 weeks. Some of the baseline
characteristics and effect of the diet on body weight in cohort
1 have previously been reported [25].
Cohort 2 (n = 30) also consisted of overweight and obese
patients (80% obese) with type 2 diabetes, who were
recruited after the POWER trial had finished, to study the
implementation of a VLCD for weight loss in type 2 diabetes.
The participants underwent the same dietary intervention as
the patients in the primary cohort. Cohorts 1 and 2 were both
recruited from the outpatient diabetes clinic of the Erasmus
Medical Center, Rotterdam, the Netherlands. To reduce risk of
hypoglycaemia, doses of insulin and sulfonylurea derivates
were lowered before the start of the diet but after baseline
measurements had been made. During the diet, the insulin
dose was regularly adjusted to achieve optimal glycaemic
control. Metformin use was continued. Only two participants
were taking glucagon-like peptide 1 (GLP-1) receptor agonist
treatment, which was continued during the intervention
period. Statin treatment was kept unchanged during the study.
Cohort 3 consisted of 37 obese individuals without type 2
diabetes, who were recruited at the Obesity Center ‘Centrum
voor Gezond Gewicht’ of the Erasmus Medical Center. They
underwent a 3 month dietary intervention consisting of a
2000 kJ (500 kcal) per day reduction in intake relative to
baseline (low-energy diet), with macronutrient and
micronutrient content in line with national dietary guidelines,
while exercise was encouraged.
Cohort 4 consisted of 26 obese individuals without type 2
diabetes who underwent gastric banding (n = 10) or a gastric
bypass procedure (n = 16). These participants were recruited
at the Leiden University Medical Center, Leiden, the
Netherlands. No specific diet was recommended beyond a
staged meal progression during the first 3 months after
surgery. Analyses were performed at baseline and 3 months
after surgery.
The dietary intervention studies and Lp(a) analysis of
previously collected clinical samples were approved by the
Medical Ethics Committee of the Erasmus Medical Center
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(reference numbers MEC-2009-143, MEC-2014-090 and
MEC 2016-604). The bariatric surgery study and use of the
samples was approved by the Medical Ethics Committee of
the Leiden University Medical Center (reference number
MEC P08.215). All investigations were carried out in
accordance with the principles of the Declaration of Helsinki
(2008). All participants provided written informed consent.
Measurements Blood samples were obtained after an
overnight fast and were stored at −80°C until further analysis.
Demographic variables were recorded, and weight, height and
waist circumference (except for cohort 4) were measured.
Ethnicity was expressed as white or non-white. HbA1c, fasting
glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol
and triacylglycerol were measured using standard laboratory
techniques.
Lp(a) measurement Plasma Lp(a) concentrations were
measured using a particle-enhanced immunoturbidimetric
assay, which was largely independent of Apo(a) KIV repeat
number (Diagnostic System #171399910930; DiaSys
Diagnostic System, GmbH, Holzheim, Germany) [26].
Plasma samples were stored at −80°C for 0.5–5 years and
thawed for the first time prior to this analysis. For each
individual, levels at baseline and after intervention were
measured in the same run. The detection limit of the assay
was 6 nmol/l, and the mean intra-assay variability was 2.8%.
Interference of triacylglycerol with Lp(a) measurements was
minimal, as measured Lp(a) levels were less than 5% affected
by the addition of plasma containing different concentrations
of triacylglycerol (ranging from 0 to 12 mmol/l) to plasma
with a relatively high Lp(a) concentration (169 or 338 nmol/l).
Repeated sampling in 27 healthy control individuals at an
interval of 2–6 months did not reveal significant differences in
median Lp(a): 29.3 nmol/l (interquartile range [IQR] 17.5–87.8)
vs 26.4 nmol/l (IQR 12.4–60.3), p = 0.087, for day 0 and after
2–6 months, respectively.
In the primary cohort (cohort 1), the Apo(a) KIV repeat
number was determined by immunoblotting, as previously
described [27, 28]. When two distinct Apo(a) isoforms were
present, the band representing the smaller isoform showed the
strongest intensity in most cases and was used as a continuous
variable. Apo(a) KIV repeat numbers were stratified in two
groups as previously described [28]: low molecular weight
(mass) (LMW) when at least one isoform with 22 or fewer
KIV repeats was present, and high molecular weight (mass)
(HMW) when only isoforms with more than 22 repeats were
present.
Statistical analysisNormality of the data and homogeneity of
variances were tested using the Shapiro–Wilk test and
Levene’s test. Variables were expressed as mean ± SD or as
median with IQR, and were tested for statistical significance
using a two-sided paired-sample t test or a Wilcoxon ranking
test, depending on the normality of the data. Medians and
95% CIs were calculated using ratio statistics, and median
differences were analysed using a related-samples
Hodges–Lehman test. Owing to the low numbers in cohorts
2, 3 and 4, in-depth analyses were performed only for cohort
1. We determined Spearman correlations of both baseline
Lp(a) levels and change in Lp(a) with different variables of
weight loss and glycaemic control.
Mann–Whitney U tests were used to analyse the difference
in baseline Lp(a) levels between the LMW and HMW
subgroups. Repeated-measurements multivariate ANOVA
(MANOVA) analysis (on Blom-transformed outcome
variables) was used to analyse the difference in change in
Lp(a) between subgroups. SPSS version 21.0 (IBM,
Armonk, NY, USA) and GraphPad Prism version 5
(GraphPad Software, La Jolla, CA, USA) were used for the
statistical analyses.
Results
Effect of diet on obese patients with type 2 diabetes (cohort 1)
The characteristics of the primary cohort (cohort 1) at
baseline and after intervention are shown in Table 1. The
131 individuals were predominantly obese, as 93% had a
BMI greater than 30 kg/m2. The remainder had a BMI >27
and ≤30 kg/m2. This cohort had a mixed ethnic background
(56% white, and 44% non-white: South-Asian and African).
Baseline Lp(a) levels correlated negatively with Apo(a) KIV
repeat number (r = −0.53, p < 0.001), baseline weight
(r = −0.18, p = 0.046), HbA1c (r = −0.20, p = 0.022), fasting
triacylglycerol (r = −0.19, p = 0.032) and ethnicity (r = −0.34,
p < 0.001), and positively with LDL-cholesterol (r = 0.18,
p = 0.038). We found no correlation of baseline Lp(a) levels
with sex (r = 0.08, p = 0.389), fasting glucose (r = −0.17,
p = 0.057) or fasting insulin levels (r = −0.06, p = 0.494).
Participants of white origin had lower baseline Lp(a)
levels than non-white participants: median 25.7 nmol/l
(IQR 5.7–120.1) vs 122.0 nmol/l (IQR 34.0–214.6)
(p < 0.001).
The diet resulted in a weight loss of 10.2 kg (95% CI 9.2,
11.3), which was equivalent to 9.9% (95% CI 8.9, 10.8) of
initial body weight. Both BMI and waist circumference
decreased significantly (p < 0.001 for all). HbA1c and fasting
glucose levels decreased (p < 0.001 for both), indicating
improved glycaemic control. Lipid variables also improved
during the dietary intervention (p < 0.01 for all, Table 1).
Lp(a) levels increased significantly from 40.9 nmol/l
(IQR 13.9–159.5) to 55.9 nmol/l (IQR 23.0–201.1)
(p < 0.001, Table 1). Figure 1 shows a waterfall plot of the
changes in Lp(a) per individual. Of the 131 participants, 49
showed an increase of over 21 nmol/l (10 mg/dl), and only six
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showed a decrease of 21 nmol/l or more (10 mg/dl). The
median increase in Lp(a) levels in cohort 1 was 14.8 nmol/l
(95% CI 10.2, 20.6).
The change in Lp(a) correlated with baseline Lp(a) levels
(r = 0.38, p < 0.001) and with the change in fasting glucose
(r = −0.17, p = 0.049) and LDL-cholesterol (r = 0.19,
p = 0.033). The correlations with change in fasting glucose
and LDL-cholesterol disappeared after correction for baseline
Lp(a) levels. The change in Lp(a) did not correlate with sex
(r = −0.04, p = 0.543) or change in weight (r = −0.14,
p = 0.116). The change in Lp(a) also correlated with ethnicity
(white vs non-white: r = −0.17, p = 0.048), although this did
not happen after correction for baseline Lp(a) levels. The
Lp(a) response to the diet did not differ between white and
non-white individuals in a repeated-measurements MANOVA
(F(1;129) = 0.199, p = 0.656). In cohort 1, 95 out of the 131
(73%) participants used statins; the diet-induced change in
Lp(a) levels was similar whether or not statins were used
(F(1;129) = 0.669, p = 0.415).
Excluding two possible outliers with an increase Lp(a)
level of ≥211 nmol/l, the outcome was similar.
Effect of Apo(a) isoform on diet-induced changes in Lp(a)
levels in cohort 1 Forty-three participants had an LMW and
88 an HMW Apo(a) isoform. As expected, baseline Lp(a)
levels were significantly higher in the LMW than the HMW
subgroup (148.8 nmol/l [IQR 26.6–297.9] vs 30.6 nmol/l
[IQR 6.5–119.4]; p < 0.001). Lp(a) levels increased during
the dietary intervention to 182.7 nmol/l (IQR 37.3–327.5;
p < 0.001) in the LMW subgroup and to 41.6 nmol/l
(IQR 15.4–139.9; p < 0.001) in the HMW subgroup
(Fig. 2). The diet-induced effect on Lp(a) did not significantly
differ between the LMW and the HMW subgroup
(F(1;129) = 1.68, p = 0.197). The alteration in Lp(a) levels
correlated strongly with baseline Lp(a) level in the HMW
subgroup (r = 0.43, p < 0.001) but not in the LMW subgroup
(r = 0.24, p = 0.118).
Long-term effect Of the 131 participants in cohort 1, 69
consented to provide an additional blood sample 20 months
after finishing the dietary intervention. This subgroup was
older (55.6 vs 51.8 years, p = 0.016), had a longer history of
type 2 diabetes (12.2 vs 8.8 years, p = 0.017) and had lost
more weight during the intervention (12.1 vs 8.6 kg,
p = 0.001), but did not differ from the other participants in
sex distribution, ethnicity, baseline Lp(a), BMI, HbA1c and
LDL-cholesterol, nor in change in Lp(a) during the diet. In
this subgroup, Lp(a) levels increased from 40.9 nmol/l
(IQR 15.6–151.7) to 55.1 nmol/l (IQR 24.7–200.2) during
the dietary intervention. Twenty months after the diet, patients
had regained an average of 6.8 ± 5.5 kg of body weight but
were still 5.2 ± 6.0 kg below baseline weight. Lp(a) levels
decreased to 43.9 nmol/l (IQR 12.2–157.8), which was no
longer statistically different from baseline levels (p = 0.050).
Weight regain was not correlated with the decrease in Lp(a)
levels from the end of the intervention to 20 months after the
intervention (r = −0.06, p = 0.626).
Effect of weight loss on Lp(a) levels in secondary cohorts
The characteristics of the cohorts 2–4 at baseline and after the
intervention are shown in Table 1. Cohort 2, consisting
predominantly of obese patients with type 2 diabetes, showed
effects of the diet similar to the primary cohort. Weight loss
was 9.0 kg (95% CI 6.7, 11.3), or 8.5% (95% CI 6.5, 10.6) of
initial body weight, and both BMI and waist circumference
decreased significantly (p < 0.01 for all). HbA1c level also
decreased (p = 0.001), but changes in fasting glucose and lipid
variables (total cholesterol, triacylglycerol, LDL-cholesterol
and HDL-cholesterol) did not reach statistical significance
in this small group (Table 1). During dieting, Lp(a) increased
from 56.9 nmol/l (IQR 12.4–148.9) to 61.5 nmol/l
(IQR 20.4–185.9) (p = 0.018; Table 1). The median increase
in Lp(a) was 13.5 nmol/l (95% CI 2.3, 30.0).
In cohort 3, which consisted of obese individuals without
type 2 diabetes, the dietary intervention led to a weight loss
of 7.1 kg (95% CI 6.3, 8.0), or 6.5% (95% CI 5.7, 7.2) of
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L
p
(
a
)
 (
n
m
o
l/
l)
Baseline After diet
200
150
100
50
0
Fig. 2 The effect of the dietary intervention on Lp(a) level in the Apo(a)
isoform subgroups in cohort 1. Medians and 95% CIs of Lp(a) levels
before and after the dietary intervention for the LMW Apo(a) isoform
group (circles, n = 43) and the HMW Apo(a) isoform group (squares,
n = 88)
-100
-50
0
50
100
150
200
250
Participant
Δ 
L
p
(
a
)
 (
n
m
o
l/
l)
Fig. 1 Diet-induced changes in Lp(a) level per individual in cohort 1
(n = 131). Individual participants (x-axis) are arranged according to the
diet-induced change in Lp(a) level. Grey bars, white participants; black
bars, non-white participants
Diabetologia
initial body weight, and to significant reductions in BMI and
waist circumference (p < 0.001 for all). Although these
participants did not have type 2 diabetes, HbA1c and fasting
glucose levels improved in this group (p = 0.002 and
p = 0.003, respectively). In addition, lipid variables improved
significantly (p < 0.05 for all). Lp(a) levels increased from
27.0 nmol/l (IQR 2.1–75.2) to 45.2 nmol/l (IQR 22.7–94.5)
(p = 0.001; Table 1). The median increase in Lp(a) was
11.9 nmol/l (95% CI 5.7, 19.0).
Cohort 4 consisted of obese individuals without type 2
diabetes who underwent bariatric surgery and were followed
up for 3 months. This intervention resulted in a weight loss
of 17.4 kg (95% CI 15.0, 19.8), or 14.0% (95% CI 12.2, 15.7)
of initial body weight (p < 0.001). During this period,
most lipid variables improved significantly (Table 1). Lp(a)
levels were lower after the intervention than before
(falling from 36.4 nmol/l [IQR 17.2–91.5] to 20.6 nmol/l
[IQR 6.3–104.1]), but this result did not reach statistical
significance in this small group (Table 1). The median
difference in Lp(a) level was −7.0 nmol/l (95%CI −18.8, 5.3).
Figure 3 summarises the results obtained for the four
independent cohorts. The relationship between weight loss
and increase in Lp(a) levels was similar for the first three
cohorts. When cohorts 1–3 were considered together, the
increase in Lp(a) correlated with the diet-induced weight loss
(n = 198, r = −0.18, p = 0.012). This relationship was not
observed for cohort 4, which consisted of individuals who lost
weight after bariatric surgery.
Discussion
Our data show that diet-induced weight loss increased Lp(a)
levels in overweight and obese individuals irrespective of the
presence or absence of type 2 diabetes. Repeated sampling in
healthy control participants at an interval of 2–6 months
showed that the increase in Lp(a) levels was not explained
by general environmental changes over time or by assay
artefacts. In patients with type 2 diabetes, the extent of the
increase in Lp(a) was mainly determined by baseline Lp(a)
level, with the highest increase seen in individuals with the
highest baseline levels. This effect on Lp(a) was independent
of the Apo(a) isoform. Such an increase in Lp(a) levels was
not observed in individuals who underwent bariatric surgery,
suggesting that weight loss per se does not increase Lp(a)
levels.
Previous studies have not shown a change in Lp(a) levels in
obese adults after various dietary interventions aimed at
weight loss [21–23]. In these studies, weight-reducing drugs
and diets different from ours were tested, and patients with
type 2 diabetes were not included. One study reported a
decrease in Lp(a) levels in obese children [20]. This
discrepancy in relation to our study may be explained by
different age-related hormonal states or by differences in
dietary composition. The type and content of fat in the diet
may be an important determinant of the dietary effect on Lp(a)
levels. An increased intake of total and saturated fat has been
found to decrease Lp(a) levels, while an increased intake of
monounsaturated fatty acids tended to increase Lp(a) levels in
healthy individuals and those with metabolic dysregulation
[29–31]. Faghihnia et al [30] have suggested that a low-fat
diet results in an increase in Lp(a) levels that may be due to
an altered metabolism of Lp(a) particles. The dietary
interventions used in our cohorts 1–3 were all based on a
low intake of total and saturated fat, while no specific dietary
restrictions were prescribed for the participants in the cohort
who underwent bariatric surgery. We previously reported that,
in a random subset of participants in cohort 1, our dietary
intervention lowered plasma levels of the soluble form of the
LDL receptor relative with 11 ligand-binding repeats (sLR11)
[32]. However, diet-induced changes in sLR11 and Lp(a)
levels did not correlate with each other (r = −0.07,
p = 0.635). In participants in cohort 1 from whom blood
samples were available at 20 months of follow-up, Lp(a)
levels had almost returned to baseline values, whereas the
initial weight reduction was only partially reversed by weight
regain. This suggests that the increase in Lp(a) levels was an
acute effect of the diet. Unfortunately, we do not have
information about the diet during the prolonged follow-up.
Future studies on the effect on Lp(a) of weight-reducing diets
with different fat contents in obese patients with and without
type 2 diabetes are warranted.
High Lp(a) levels have consistently been associated with
an increased risk of coronary heart disease [6, 9], and results
from genetic studies indicate a causal association between
high Lp(a) levels and CVD [17, 33, 34]. The risk of CVD
associated with high Lp(a) levels is notably higher in
individuals with than without type 2 diabetes [18]. The
dose–response relationship of Lp(a) levels with CVD risk
has been shown to be curvilinear in shape, with no evidence
of a threshold [35]. This suggests that the increase in Lp(a)
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Fig. 3 ΔLp(a) and Δweight in the four independent study cohorts.
Means and 95% CI for Δweight (white circles) and medians with 95%
CIs forΔLp(a) (black circles) in the four cohorts. The size of the symbols
reflects the number of participants
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levels induced by weight loss dieting observed in our study
might increase the risk of CVD. This could potentially reduce
the beneficial cardiometabolic effects that result from the
improvement in conventional CVD risk factors after
diet-induced weight loss. In the Look AHEAD (Action for
Health in Diabetes) study (NCT00017953), the incidence of
CVD was not reduced by a low-energy, low-fat diet and
physical activity in patients with type 2 diabetes after 10 years
of follow-up, despite an improvement in conventional risk
factors for CVD [5]. Hypothetically, a parallel increase in
Lp(a) levels could be one of the explanations why CVD
events were not reduced by this lifestyle change. However,
effects on Lp(a) levels were not reported in the Look
AHEAD trial. Randomised clinical trials addressing the effect
of alterations in Lp(a) levels with lifestyle changes or
medication on hard clinical endpoints or CVD risk are needed.
Recently, the short-term efficacy and safety of two specific
Lp(a)-lowering agents has been reported [36]. Long-term
effects on cardiovascular endpoints are awaited.
In participants who underwent bariatric surgery, weight
loss was not accompanied by an increase in Lp(a) level. Two
previous studies have shown that bariatric surgery-induced
weight loss in obese individuals was accompanied by a
decrease in Lp(a) levels [37, 38], whereas another study found
no significant effect [39]. The effects of bariatric surgery on
bile acid flow and signalling, inflammation, release of
gastrointestinal hormones, the gut microbiome and the wound
healing processes may all have had an impact on Lp(a),
resulting in the absence of a weight loss-induced increase in
Lp(a) levels [40–44].
The baseline Lp(a) levels in our two cohorts with type 2
diabetes (cohorts 1 and 2) were relatively high compared with
the two cohorts without type 2 diabetes (cohorts 3 and 4),
whereas in the Women’s Health Study and Copenhagen City
Heart Study the Lp(a) levels in participants with diabetes were
significantly lower than the Lp(a) levels in the control
participants [45, 46]. Non-white individuals, in particular
those of South-Asian ancestry, display markedly higher
Lp(a) levels than white individuals [47–49], and are
over-represented in our cohorts with type 2 diabetes. The
change in Lp(a) during the diet was correlated with ethnicity.
However, in the repeated-measurements analysis we found no
difference between the white and non-white populations in
ΔLp(a). This suggests that non-white individuals have higher
baseline Lp(a) levels, and therefore show the highest absolute
change in Lp(a) levels on dieting, but that the relative change
is similar to that in white individuals.
The strengths of this study are its prospective design and
the use of four independent cohorts for investigating the effect
of weight loss on Lp(a), which more than doubled the total
number of participants who have so far been studied in
relation to this topic. Our study is descriptive in nature.
Future studies should clarify the mechanisms underlying the
increase in Lp(a) levels on diet-induced weight loss, as well as
the consequence of weight loss for the functionality of Lp(a).
As all the participants had been referred to a tertiary centre,
our findings may not be applicable to the entire population of
overweight and obese patients with or without type 2 diabetes.
We found that the effect of diet-induced weight loss on Lp(a)
levels occurred irrespective of the presence or absence of type
2 diabetes. However, some of the individuals in cohorts 3 and
4 may have had impaired glucose tolerance, since the
classification was based on fasting glucose level and not on
an oral glucose tolerance test. Finally, a long-term follow-up
study is required to determine whether elevated Lp(a) levels
after weight loss dieting affect the incidence of CVD in obese
patients with and without type 2 diabetes.
In conclusion, Lp(a) levels increased significantly in obese
individuals with and without type 2 diabetes during
diet-induced weight loss, but not in individuals who
underwent bariatric surgery. This may hypothetically reduce
the beneficial cardiometabolic effects of a diet-induced weight
loss. Therefore, Lp(a) may be an additional target in
overweight and obese individuals on a energy-restricted diet
to reduce the risk of CVD. Long-term follow-up studies are
required to establish whether adding a specific Lp(a)-lowering
agent to a dietary intervention will improve long-term CVD
outcome in obese individuals with and without type 2
diabetes.
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